ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements with these filters
Sudarshan Pharma's Company Secretary and Compliance Officer, Nirav Shah, resigned effective November 9, 2026. The resignation was for better prospects, with no other reason cited.
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹217 Cr (+28.5% YoY) and net profit of ₹8.1 Cr (+92.9% YoY) for Q2 FY27.
Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.
Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.
Sudarshan Pharma Industries Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.
Sudarshan Pharma Industries completed the sale of its 51% stake in subsidiary Ishwari Healthcare Private Limited for ₹1.40 Crore. The entity ceases to be a subsidiary.
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.
Sudarshan Pharma Industries Ltd announced the release of a pledge of 20,00,000 equity shares held by its promoter, Mr. Hemal Mehta. This disclosure complies with SEBI regulations.
Sudarshan Pharma Industries will acquire a 9.50% stake in MedTherapy Biotechnology Inc. for cash. Its promoters will separately acquire an additional 3% combined stake.
Sudarshan Pharma Industries Ltd has filed its Annual Report for the Financial Year 2025-26 with the exchange, pursuant to SEBI Regulation 34.
Sudarshan Pharma Industries Ltd has issued the notice for its 18th Annual General Meeting, scheduled to be held on September 22, 2026, via video conferencing.
Promoters Hemal V Mehta and Sachin V Mehta have created a pledge on 13,200,000 equity shares of the company as security for a loan.
Sudarshan Pharma Industries Ltd allotted 48,11,730 equity shares upon conversion of FCCBs. The conversion value is approximately ₹14.25 Crore.
Sudarshan Pharma Industries reports on its specialty chemicals and pharmaceutical business, highlighting the turnaround of Ratna Lifescience and strategic vertical integration into API manufacturing and branded generics.
Sudarshan Pharma Industries Ltd will acquire 3,000 shares, representing a 30% stake, in Sudarshan Maven Pharma Private Limited. This strategic acquisition will make the entity a wholly-owned subsidiary.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹174.4 Cr (+20.0% YoY) and net profit of ₹5.6 Cr (+40.0% YoY) for Q1 FY27.
Promoter Hemal Vasantrai Mehta released a pledge of 20,00,000 shares of Sudarshan Pharma Industries Limited. The shares were previously encumbered for personal loan reasons.
Sudarshan Pharma Industries Ltd has scheduled a board meeting for August 12, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Sudarshan Pharma Industries Ltd submitted its quarterly shareholding pattern under Regulation 31. This periodic disclosure provides details on promoter and public equity ownership.
Sudarshan Pharma issued 90,00,000 equity shares to promoters Hemal Mehta and Sachin Mehta. The allotment and listing approval process for these shares is currently underway.
Promoter Hemal Vasantrai Mehta pledged 20,00,000 shares of Sudarshan Pharma Industries, representing 0.83% of equity. The pledge was created for personal loan requirements.
Sudarshan Pharma Industries Ltd announced voting results for a postal ballot. All resolutions, including the migration to the main board, were passed.
Sudarshan Pharma allotted 90 lakh equity shares upon conversion of 9 lakh warrants by promoters. This strengthens promoter holding and increases paid-up capital to Rs.24.97 Crore.
Sudarshan Pharma's Warrants Committee meeting postponed from 11 June to 12 June 2026. The delay is procedural and does not affect the underlying warrant conversion agenda.
Sudarshan Pharma incorporated a wholly-owned US subsidiary, Sudarshan Industries Inc. This expands its international footprint and customer base in the USA.
Sudarshan Pharma Industries scheduled a Warrants Committee meeting for June 11, 2026. The committee will consider converting warrants and allotting equity shares to applicants.